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Abstract
Introduction/Aim.  Infection with respiratory syncytial virus
(RSV) occurs during the first year of life in 50% of children and
20%–40% of them have signs of lower respiratory tract infec-
tion (bronchiolitis or pneumonia). There is an increased risk for
complicated course and death from RSV infection in premature
infants, especially those with bronchopulmonary dysplasia
(BPD) or congenital heart disease. The aim of our study was to
analyze clinical characteristics of laboratory confirmed RSV in-
fection in order to evaluate the need for preventive measures in
neonates and young infants. Methods. The prospective study
included children under age of 12 months admitted to our hos-
pital in the period November 2008–March 2009 who were
positive for RSV by enzyme immunoassay membrane test. The
course of disease was assessed by clinical score and radiographic
findings. Results. Infection with RSV was confirmed in 91 pa-
tients: 21 (23.0%) were under the age of 30 days, 37 (40.7%)
were between 31–60 days, and 33 patients (36.3%) were older
than 60 days (p > 0.05). The highest hospitalization rate was in
January – 33 patients (36.3%; p < 0.01). Disease severity score in
these age groups (AG) were: 8.4  ±  0.4 (AG 0–30 days);
9.0 ± 0.3 (AG 31–60 days) and 8.3 ± 0.3 (AG > 60 days), with-
out statistically significant difference among the groups
(p > 0.05). Clinical scores in patients with and without risk fac-
tors were 10.5  ±  0.5 and 8.3  ±  0.2, respectively (p < 0.01).
Pathological radiographic findings were observed in 72 (79.1%)
and complications (apnea, significant atelectasis, encephalopa-
thy) occured in 15 (16.5%) patients. The average length of hos-
pital stay in complicated and uncomplicated course of the dis-
ease was 9 days and 6 days, respectively (p < 0.01). Therapy in
85 (93.4%) patients included bronchodilators, while systemic
glucocorticoids and oxygen therapy were used in 51 (56.0%) and
44 (48.4%) patients, respectively. Death occured in 2 (2.2%) pa-
tients, both from a high risk group (the patient with BPD and
the other one with congenital heart disease and Down syn-
drome).  Conclusion. Infection with RSV in our settings
showed marked seasonal characteristics with highest hospitali-
zation rate in January. Although the course and outcome of the
disease were favorable in the majority of our patients, the need
for hospitalization and administration of therapy with possible
side effects warrants that general measures for prevention of
respiratory infections are followed especially in the first year of
life. Severe disease and death are more probable in neonates and
infants with risk factors. In these children passive immunisation
with specific monoclonal antibody (e.g. palivizumab) during
RSV season should be considered.
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Apstrakt
Uvod/Cilj. Respiratornim sincicijalnim virusom (RSV) inficira
se 50% dece do navršene prve godine života, a 20–40% obolelih
ima znakove zahvatanja periferijskih disajnih puteva (bronhioli-
tis ili pneumonija). Poseban rizik od komplikacija i smrtnog is-
hoda usled infekcije RSV postoji kod prevremeno rođene dece,
odojčadi sa bronhopulmonalnom displazijom (BPD) i urođenim
srčanim manama. Cilj ovog rada bio je analiza kliničkih karakte-
ristika laboratorijski potvrđene infekcije RSV i procena potrebe
za uvođenjem preventivnih mera kod novorođenčadi i odojčadi.
Metode. Prospektivnom studijom bili su obuhvaćeni bolesnici
do navršenih 12 meseci života hospitalizovani u periodu no-
vembar 2008 - mart 2009. godine, kod kojih je imunoenzimskim
testom dokazana infekcija RSV. Procena toka bolesti vršena je
na osnovu kliničkog skora i radiografskog nalaza. Rezultati. In-
fekcija RSV dokazana je kod 91 bolesnika od kojih je 21 (23,0%)
imalo manje od 30 dana života, dok se uzrast 37 (40,7%) boles-
nika nalazio u rasponu 31–60 dana života. Više od 60 dana
imalo je 33 (36,3%) obolele odojčadi (p > 0,05). Najveća stopaVolumen 63, Broj 3 VOJNOSANITETSKI PREGLED Strana 221
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hospitalizacije bila je u januaru – 33 bolesnika (36,3%; p < 0,01).
Težina ispoljavanja procenjena je na osnovu kliničkog skora koji
je u navedenim uzrasnim grupama iznosio 8,4 ± 0,4 (0–30 dana);
9,0 ± 0,3 (31–60 dana); 8,3 ± 0,3 (> 60 dana), a razlika nije imala
statističku značajnost (p > 0,05). U zavisnosti od prisustva ili od-
sustva faktora rizika klinički skor iznosio je 10,5 ± 0,5, odnosno
8,3 ± 0,2  (p  <  0,01). Patološki radiografski nalaz imalo je 72
(79,1%) dece, a  komplikacije (krize apneje, opsežne atelektaze,
encefalopatija) postojale su kod 15 (16,5%) bolesnika. U slučaju
komplikovanog toka bolesti prosečna hospitalizacija trajala je 9
dana, a kod dece bez komplikacija 6 dana (p <0,01). U lečenju su
primenjivani bronhodilatatori kod 85 (93,4%) bolesnika, dok je
sistemska terapija glukokortikoidima i kiseonikom primenjena
kod 51 (56,0%), odnosno 44 (48,4%) obolele dece. Smrtni ishod
nastupio je kod dva (2,2%) bolesnika koji su pripadali grupi sa
faktorima rizika (bolesnik sa BPD i bolesnik sa urođenom srča-
nom manom i Dounovim sindromom). Zaključak. Infekcija
RSV u našoj sredini ima izraziti sezonski karakter sa najvećom
učestalošću hospitalizacija tokom januara. Mada su tok i ishod
bolesti kod većine bolesnika bili povoljni, neophodnost hospita-
lizacije i primene terapijskih postupaka sa mogućim neželjenim
dejstvima nameću potrebu za doslednom primenom opštih mera
prevencije respiratornih infekcija, naročito tokom prve godine
života. Teži oblik i nepovoljan ishod bolesti mogu se očekivati
kod novorođenčadi i odojčadi sa faktorima fizika. Kod te dece u
toku sezone infekcije RSV opravdano je razmatranje primene pa-
sivne zaštite specifičnim monoklonskim antitelom (palivizumab).
Ključne reči:
respiratorni sincicijalni virusi; infekcija; novorođenče;
deca, predškolska; imunološki testovi; lečenje lekovima;
prognoza.
Introduction
Respiratory syncytial virus (RSV) is the one of the most
common causes of acute respiratory tract infections in chil-
dren. Infection with this virus occurs during the first year of
life in 50% of children and 20%–40% of them have signs of
lower respiratory tract infection (bronchiolitis or pneumo-
nia). There is an increased risk for complicated course and
lethal outcome in premature infants, especially those me-
chanically ventilated due to the respiratory distress syndrome
(RDS), infants with chronic lung disease, in particular bron-
chopulmonary dysplasia (BPD) and infants with hemody-
namically significant congenital heart diseases 
1.
Infection with RSV is transmitted by droplets or direct
contact. This virus preserves contagiousness for a few hours
on objects as far as 6.6 m from the patient 
2, 3. Immunity after
primary infection is short-term and reinfections occur fre-
quently during childhood 
4. In temperate climate RSV infec-
tion shows marked seasonability with peak incidence during
winter and early spring 
5. Every year between 75,000 to
125,000 hospitalizations in the USA and more than 600,000
deaths worldwide are connected to the RSV infection 
6, 7.
According to our knowledge there aren’t sufficient data
regarding RSV infection in neonates and young infants in
Serbia. The aim of our study was to analyze clinical charac-
teristics of laboratory confirmed RSV infection in order to
evaluate the need for preventive measures in neonates and
young infants.
Methods
The prospective study included children under the age
of 12 months admitted to the Mother and Child Health Insti-
tute “Dr Vukan Čupić” in the period 1
st November 2008 –
31
st March 2009 with laboratory confirmed RSV infection.
Informed consents were obtained from parents or guardians
for all children enrolled. The enzyme immunoassay mem-
brane test (BD Directigen™ RSV Test Kit, Becton Dickin-
son, USA) was used for confirmation of RSV infection by
qualitative detection of RSV antigen in nasopharyngeal aspi-
rates within 24 h of hospital admission. The participation in
the study did not affect routine management or the length of
hospital stay.
The children enrolled were assessed for gender, age,
gestational age, month of admission and course of disease in
the presence of risk factors (prematurity, neonatal RDS and/or
mechanical ventilation, BPD, congenital heart disease). The
course of disease was assessed by clinical score with six crite-
ria including transcutaneous oxygen saturation measured by a
pulse oxymeter (SaO2) (Table 1) 
8. Some other evaluated pa-
rameters included patient’s axillary temperature, radiographic
findings, white blood cell (WBC) count and C-reactive protein
(CRP) level measured immunoturbdimetrically (Turbox
®,
Orion Diagnostica), type of complication, therapy adminis-
tered and length of hospital stay.
Statistical analysis was performed by SPSS v.12.0 for
Windows. The Student’s t-test, ANOVA and χ
2 test were
Table 1
Parameters of clinical score used for assessment of respiratory distress severity
Score Parameter 12 3
Heart rate (beats/min) < 120 120–160 > 160
Respiratory rate (breaths/min) < 40 40–60 > 60
Wheezing absent expiratory audible without auscultation
Skin color normal mild cyanosis moderate to severe cyanosis
Feeding difficulties absent mild serious
SaO2
 (%) > 98 94–98 < 94
SaO2 – oxygen saturation
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used and the difference was considered statistically signifi-
cant when p < 0.05.
Results
Respiratory syncytial virus infection was confirmed in
91 patients, with even distribution by gender and predomi-
nance of term neonates and infants born by vaginal delivery
with average body mass of 3.140  ±  75 g (Table 2). The
monthly distribution of RSV infection was the following: in
November and March there were 6 (6.6%) and 8 (8.8%) pa-
tients, respectively; in December and February, 25 (27.5%)
and 19 (20.9%) patients, respectively (p > 0.05);  while  in
January the hospitalization rate was the highest with 33
(36.3%) patients, which was statistically highly more signifi-
cant than in the previous months (p < 0.01) (Figure 1).
Table 2
Characteristics of patients with respiratory syncytial virus
(RVS) infection (n = 91)
Characteristics n (%)
Age (days)
< 30* 21 (23.0)
31–60 37 (40.7)
> 60 33 (36.3)
Gender
male 47 (51.6)
female 44 (48.4)
Gestational age (weeks)
> 36 79 (86.8)
32–36 7 (7.7)
≤ 32 5 (5.5)
*the youngest patient = 10 days
Month of  admission
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Fig. 1 – Monthly distribution of hospitalized patients with
confirmed respiratory syncytial virus (RSV) infection
(n = 91)
Body temperature was normal on admission and/or
during hospitalization in 63 patients (69.2%), while fever
with average value of 38.3 ± 0.1 
oC was noted in 28 (30.8%)
of the patients. Pathological radiographic findings were pres-
ent in 72 (79.1%) of the patients with hyperinflation seen in
50 (54.9%) of the patients, infiltrates in 13 (14.3%), consoli-
dation in 5 (5.5%) and atelectasis in 4 (4.4%) of the cases.
The median of WBC count was 11.3 × 10
9/L, and the median
of CRP level was 2.5 mg/L.
The clinical score for the whole group had the average
value of 8.6 ± 0.2 without statistically significant difference
between age groups, or between patients born before and af-
ter 36 weeks of gestation. The clinical score for those born
before 32 weeks of gestation was 10.6 ± 0.7 and was highly
statistically greater than for the patients born after this gesta-
tional age (Table 3).
Table 3
Clinical score, age and gestational age of patients with
respiratory syncytial virus (RSV) infection (n =  91)
Parameters Clinical score p
Age (days)
0–30 8.4 ± 0.4
31–60 9.0 ± 0.3
> 60 8.3 ± 0.3
> 0.05
Gestational age (weeks)
> 36 8.5 ± 0.2
32–36 9.0 ± 0.3 > 0.05
≤ 32 10.6 ± 0.7 ≤ 0.01
Risk factors for more severe disease were present in 12
(13.2%) of the patients with clinical score of 10.5 ± 0.5,
while in the patients without these risk factors clinical score
was 8.3 ± 0.2. This difference was highly statistically signifi-
cant (p < 0.01).
The median length of hospital stay in the presence of
risk factors or in complicated disease was 10 and 9 days, re-
spectively, while in the absence of risk factors the average
length of hospital stay was 6 days. This difference was
highly statistically significant (p < 0.01).
The prevalence of various therapeutic procedures (the
use of bronchodilators, systemic glucocorticoids, oxygen
therapy) is shown in Table 4.
Table 4
Therapeutic procedures in patients with respiratory
syncytial virus (RSV) infection (n = 91)
Therapeutic procedure n (%)
Brochodilators 85 (93.4)
Systemic glucocorticoids 51 (56.0)
Oxygen therapy 40 (44.0)
The course of the disease was complicated by apnea,
significant atelectasis and/or encephalopathy in 15 (16.5%)
patients, while death occurred in 2 infants, so that mortality
rate in our patients was 2.2%.
The discharge diagnosis was bronchiolitis in 77
(84.6%) of the patients. Ten (11.1%) patients were dis-
charged with the diagnosis of pneumonia and 4 (4.4%) with
the diagnosis of nonspecific respiratory infection.
Discussion
According to the available literature this is the first pro-
spective study in our country including patients under the
age of 12 months with laboratory confirmed RSV infection.
The enzyme immunoassay test with two monoclonal anti-
bodies (BD Directigen™ RSV Test Kit, Becton Dickinson,
USA) was used for confirmation of RSV infection. This test
is simple, reliable, has high specificity of 97.5% and preva-Volumen 68, Broj 3 VOJNOSANITETSKI PREGLED Strana 223
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lence of false-positive results of only 0.7% 
9. The results of
testing were available in a very short period of time (< 1 h).
Besides, RSV and bacterial co-infection occur in less than 2%
of previously healthy infants. Therefore, the confirmation of
RSV infection by this test excludes with high probability the
suspicion of systemic bacterial infection, which enhances the
safety and rationality of diagnostic and therapeutic procedures
especially in children of the youngest age 
10.
Our results also confirm the seasonal character of RSV
infection with the increase in hospitalization rate from No-
vember until January when the highest prevalence was
reached. Afterwards, there was slow decline in hospitaliza-
tion rate, so there were no confirmed cases in these age
groups after the end of March. Large epidemiological studies
have shown that the regional season pattern of RSV infection
distribution does not change significantly over time 
11, 12.
Our youngest patient was 10 days old on admission,
and RSV infection in the first week of life was also described
13. Since the incubation period lasts 2–8 days, from the epi-
demiological point of view it is important that the infection
with RSV can occur in, or shortly after discharge from ma-
ternity ward 
14. The most important preventive measure
against the spread of nosocomial infection is the appropriate
hand hygiene of the staff. It should be also bared in mind that
infected persons eliminate virus in 3 to 8 days, and in infants
it takes up to four weeks 
15.
Similarly to the previously published results there was a
slight predominance of male gender in our group as well,
while the rate of 13.2% of patients born before 36 weeks of
gestation was twice as high as the general rate of premature
delivery in our country 
16. This result is in agreement with
the finding that premature infants are more often hospitalized
due to RSV infection than term infants. The need for hospi-
talization in these infants is explained by higher prevalence
of severe forms of bronchiolitis due to the slow and incom-
plete increase of small airways diameter during the first year
of life 
14, 15. Also, in our patients hyperinflation was the most
common radiographic finding, while infiltrations and con-
solidations were less prevalent. Although there is an evi-
dence that the presence of atelectasis does not complicate the
course of disease, it has been described that in more than 5%
of infants there is a whole lobe consolidation with respiratory
failure and the need for mechanical ventilation 
17.
The majority of our patients did not have fever on ad-
mission or during hospital stay which supports the view that
RSV infection is an “afebrile illness” 
4. There was not a sig-
nificant rise in WBC count nor in CRP level which is in
agreement with previous studies and indicates that RSV in-
fection is rarely complicated by bacterial infections 
18.
Since usually there is involvement of small airways in
RSV infection leading to bronchoobstruction, we used clinical
score for assessment of disease severity that was originally
designated for use in acute asthma attacks 
8, 11. The advantage
of this score lies not only in quantification of respiratory dis-
tress severity and early recognition of hypoxemia but also in
possibility of comparison with results from different authors.
For example, the consistency of our criteria for hospital admis-
sion is confirmed by the fact that the average clinical score in
our group (8.6 ± 0.2) was very similar to that of Constanto-
poulos et al. (8.7 ± 1.7) 
12. The lack of a significant difference
in our age groups probably comes from standardized criteria
for hospital admission. Opposite to this, the higher score was
obtained in premature infants born before 32 weeks of gesta-
tion and is most probably caused by before mentioned mor-
phological characteristics of airways. The higher clinical score
was present in high-risk group of infants for severe disease and
unfavorable outcome of RSV infection due to the chronic lung
disease (BPD) and hemodynamically significant congenital
heart disease 
18. In these situations, according to our results as
well, there is higher rate of complications and greater length of
hospital stay, but one can also expect unfavorable course with
lethal outcome 
7. In a group of serious, early complications of
disease common are central apneas which can be seen in up to
10%–26% of patients 
19. The risk for their occurrence is higher
in premature, young infants and in infants with apneas of pre-
maturity 
20, but they can be the first sign of disease in previ-
ously healthy children. Taking this into account current rec-
ommendations for hospitalization include all infants under the
age of 3 months with RSV lower respiratory tract infection 
21.
The signs of encephalopathy were present in one of our pa-
tients, but this rare, previously described complication most
probably is not related to the structural changes in the CNS 
22.
The average length of hospital stay in our group was 6
days in case of uncomplicated disease which is consistent
with previously published results 
23, while in the case of
complicated disease the length of hospital stay was signifi-
cantly increased (on average for 3 days).
When compared to other respiratory viral infections,
RSV infection treatment in neonates and infants is based on
more extensive approach and the cost of treatment per patient
in USA goes up to 3,000 US dollars 
24. Symptomatic, mostly
empiric therapy is used. The exception is the need for oxygen
therapy when oxygen saturation of hemoglobin is lower than
90% 
15. Inhalations with beta-2 agonists are used in up to 85%
of patients with positive effect on clinical score, but they do
not affect the length of hospital stay 
25. Similarly to our experi-
ence, hospitalized patients with RSV bronchiolitis receive glu-
cocorticoids as strong anti-inflammatory medications in up to
60% of cases 
26. But recent systematic analysis has shown that
treatment with systemic glucocorticoids does not have impact
on clinical score or the length of hospital stay 
27. Although
certain authors suggest the use of nebulized epinephrine as
more effective treatment, new studies show that isotonic and
hypertonic (3%) NaCl solution are equally effective 
28.
Death has occurred in two of our patients at the age of 3
months. Both patients had known risk factors for unfavorable
outcome of RSV infection. The first patient was born at 28th
week of gestation with body mass of 1,100 g, and as a result
of mechanical ventilation due to the RDS suffered from se-
vere form of BPD. The second patient had congenital heart
disease (ventricular septal defect) and Down syndrome.
Lethal outcome of RSV infection is a problem in a group
of children with risk factors for severe disease form. There-
fore, in most countries with developed healthcare system pas-
sive immunization with palivizumab, recombinant monoclonal
antibody, is performed in specially defined groups. Recom-Strana 224 VOJNOSANITETSKI PREGLED Volumen 68, Broj 3
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mendations for the use of palivizumab in high-risk groups of
children were recently published in our country, as well 
29.
Conclusion
According to our study, the first of this kind in our
country, we can conclude that the course and outcome of
RSV infection in hospitalized neonates and young infants are
favorable in most cases. The average length of hospital stay
in uncomplicated disease course is six days. Serious compli-
cations (apnea, significant atelectasis and encephalopathy)
prolong hospital stay for three days on average. Severe dis-
ease and unfavorable outcome are more probable in children
with risk factors. In these children passive immunisation
with specific monoclonal antibody (palivizumab) during
RSV season should be considered.
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